Real-world study suggests GLP-1 receptor agonists may reduce emergency visits and medication needs for chronic migraine

GLP-1 Therapy Reduces Migraine Frequency by More Than Half in Obesity Patients

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half

Can GLP-1 medications improve health in people with Type 2 diabetes and PAD?

Research Highlights: GLP-1RA (glucagon-like peptide-1 receptor agonist) medications, which are prescribed to treat Type 2 diabetes and to he

Oral small-molecule GLP-1 RA improves blood glucose and weight reduction

The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults.

GLP-1 Receptor Agonists Linked to Lower Mortality, Amputation Rate in PAD and Type 2 Diabetes

GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer

The post GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer appeared first on European Medical Journal .

GLP-1 Receptor Agonists Show Promise for Treating Extragenital Lichen Sclerosus: A Case Report

This case report describes 2 patients with lichen sclerosus whose symptoms improved with glucagon-like peptide-1 receptor agonists.